EGFR and colorectal cancer: Approximately 50% of colorectal cancer patients have RAS mutations, but anti-EGFR antibodies such as cetuximab and panitumumab, which are used in the treatment of colorectal cancer, are effective only in patients without RAS mutations, thus highlighting the need for colorectal cancer treatments for patients with RAS mutations.